Abstract
Nonbacterial thrombotic endocarditis is a form of a thrombotic angiopathy involving the endothelial lined endocardial surfaces of the heart which includes valves and the chamber walls. Underlying etiologies for nonbacterial thrombotic endocarditis include autoimmune diseases, hypercoagulable states, in the setting of certain malignant neoplasms, and physical injury. The pathogenesis for these processes is that of primary endothelial injury resulting in a thrombotic angiopathy. We present a patient with heart failure being evaluated before hematopoietic stem cell transplantation who had previously been provided with chemotherapy and whose cardiac magnetic resonance imaging reveals findings suggestive of amyloidosis. A subsequent endomyocardial biopsy instead showed nonbacterial thrombotic endocarditis characterized by the endocardium with fibromyxoid thickening and overlying fresh fibrin. This case highlights histopathologic findings of chemotherapy-associated nonbacterial thrombotic endocarditis involving the right ventricle wall of the endocardium, therefore expanding the radiological differential in patients with cardiac magnetic resonance imaging findings suggestive of amyloidosis.
PMID: 32142924 [PubMed - as supplied by publisher]
8 March 2020
14:35
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:35
In reply to this message
pubmed: tutte cardiotoxicity...
Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System.
Related Articles
Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System.
Heart Fail Clin. 2020 Apr;16(2):231-241
Authors: Moriyama S, Fukata M, Kusaba H, Maruyama T, Akashi K
Abstract
Several cancer treatments cause cardiotoxicity that can lead to heart failure, coronary artery disease, arrhythmia, and pericardial disease. In this review, representative cases of heart failure following cardiotoxicity caused by trastuzumab, anthracycline, and hematopoietic stem cell transplantation are described with case notes. Additionally, other important points regarding cardiotoxicity related to heart failure are reported. During and after potentially cardiotoxic therapy, periodic cardiac examinations are recommended to detect any cardiovascular disorders; these are ameliorated if appropriately diagnosed at an earlier stage. It is important for cardiologists and oncologists to understand the pathophysiology of representative cardiovascular disease cases following cancer treatment.
PMID: 32143767 [PubMed - as supplied by publisher]
10 March 2020
11:54
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
11:54
In reply to this message
pubmed: tutte cardiotoxicity...
Enhancement of Loading Efficiency by Co-loading of Doxorubicin and Quercetin in Thermoresponsive Polymeric Micelles.
Enhancement of Loading Efficiency by Co-loading of Doxorubicin and Quercetin in Thermoresponsive Polymeric Micelles.
Biomacromolecules. 2020 Mar 09;:
Authors: Soltantabar P, Calubaquib EL, Mostafavi E, Biewer MC, Stefan MC
Abstract
Chemotherapy faces challenges, including poor aqueous solubility of the drugs, and cardiotoxicity. Micellar drug delivery systems (DDS) are used to encapsulate anticancer drugs for better therapeutic effects, however, with poor loading content. Herein, we synthesized a micellar DDS using -benzyloxy substituted poly(ε-caprolactone) as the hydrophobic block, and co-loaded anticancer doxorubicin (Dox) and antioxidant quercetin (Que). -Substituted oligo(ethylene) glycol (OEG) poly(ε-caprolactone)s were used as hydrophilic blocks to make the polymers thermoresponsive. Variation of the OEG chain allowed the tunability of the lower critical solution temperature. Moreover, drug loading and release were studied. Thermodynamic stability, size, and morphology were determined by fluorescence measurements, dynamic light scattering, and transmission electron microscopy. Combination loading demonstrated improved loading of Dox and Que. Biological studies were performed using HepG2 human liver cancer and H9c2 rat heart cells. The use of biodegradable, biocompatible and thermoresponsive polymers along with the co-loading approach is a good strategy in developing DDSs.
PMID: 32149500 [PubMed - as supplied by publisher]
11:54
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
11:54
In reply to this message
pubmed: tutte cardiotoxicity...
Anthracycline and Peripartum Cardiomyopathies.
Related Articles
Anthracycline and Peripartum Cardiomyopathies.
Circ Res. 2019 05 24;124(11):1633-1646
Authors: Cowgill JA, Francis SA, Sawyer DB
Abstract
Anthracycline-associated cardiomyopathy and peripartum cardiomyopathy are nonischemic cardiomyopathies that often afflict previously healthy young patients; both diseases have been well described since at least the 1970s and both occur in the settings of predictable stressors (ie, cancer treatment and pregnancy). Despite this, the precise mechanisms and the ability to reliably predict who exactly will go on to develop cardiomyopathy and heart failure in the face of anthracycline exposure or childbirth have proven elusive. For both cardiomyopathies, recent advances in basic and molecular sciences have illuminated the complex balance between cardiomyocyte and endothelial homeostasis via 3 broad pathways: reactive oxidative stress, interference in apoptosis/growth/metabolism, and angiogenic imbalance. These advances have already shown potential for specific, disease-altering therapies, and as our mechanistic knowledge continues to evolve, further clinical successes are expected to follow.
PMID: 31120822 [PubMed - indexed for MEDLINE]
11 March 2020
13:49
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:49
In reply to this message
pubmed: tutte cardiotoxicity...
Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study.
Related Articles
Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study.
Cardiooncology. 2020;6:3
Authors: Lin Y, Yu H, Liu F, Chen C, Zhang Y, Wang B, Yang Y, Liu Y, Zhang L, Xia Y
Abstract
Background: Our recent study has revealed that many hospitalized patients with acquired long QT syndrome (ALQTS) are cancer patients. This study aims to determine the risk factors and outcomes of hospitalized cancer patients with ALQTS.
Methods: We performed a matched case-control study within a cohort of 10,180 cancer patients hospitalized between September 2013 and April 2016. Among them, 150 patients defined as having severe ALQTS with a markedly prolonged QT interval (QTc ≥ 500 ms) were compared with 293 age-, sex- and cancer-type-matched controls (non-ALQTS). Death as the endpoint was followed for up to 2 years. Cox regression and Kaplan-Meier survival analyses were performed to assess the effects of particular clinical variables on all-cause mortality. Multivariate logistic regression was performed to calculate odds ratios (OR) for various predictors of QT prolongation.
Results: The mortality was significantly higher in ALQTS group (63.3% vs. 33.4%). Hypertension, hypokalemia, hypocalcemia, QT-prolonging drugs, infection, anemia, anti-microtubule agents were contributing factors to ALQTS. Renal insufficiency, male gender and hypokalemia were found to be independent risk factors for all-cause mortality in ALQTS group.
Conclusion: Markedly prolonged QT interval was seen in 1.5% of hospitalized cancer patients. The all-cause mortality was high in cancer patients with severe ALQTS.
PMID: 32154029 [PubMed]
13:49
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:49
In reply to this message
pubmed: tutte cardiotoxicity...
Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy.
Related Articles
Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy.
Cardiooncology. 2020;6:2
Authors: Canada JM, Thomas GK, Trankle CR, Carbone S, Billingsley H, Van Tassell BW, Evans RK, Garten R, Weiss E, Abbate A
Abstract
Background: Irradiation of the heart during cancer radiotherapy is associated with a dose-dependent risk of heart failure. Animal studies have demonstrated that irradiation leads to an inflammatory response within the heart as well as a reduction in cardiac reserve. In the current study we aimed to evaluate whether inflammatory biomarkers correlated with changes in cardiac function and reserve after radiotherapy for breast or lung cancer.
Methods and results: We studied 25 subjects with a history of breast or lung cancer without a prior diagnosis of cardiovascular disease or heart failure, 1.8 years [0.4-3.6] post-radiotherapy involving at least 5 Gray (Gy) to at least 10% of the heart. High-sensitivity C-reactive protein (CRP) was abnormal (≥2 mg/L) in 16 (64%) subjects. Cardiac function and reserve was measured with Doppler echocardiography before and after exercise and defined as left-ventricular ejection fraction (LVEF), early diastolic mitral annulus velocity (e'), and increase in LV outflow tract velocity time integral cardiac output (cardiac reserve) with exercise. Subjects with abnormal CRP had significantly lower LVEF (51 [44-59] % vs 61 [52-64] %, P = 0.039), lower e' (7.4 [6.6-7.9] cm/sec vs 9.9 [8.3-12.0] cm/sec, P = 0.010), and smaller cardiac reserve (+ 1.5 [1.2-1.7] L/min vs + 1.9 [1.7-2.2] L/min, P = 0.024).
Conclusion: Elevated systemic inflammation is associated with impaired left-ventricular systolic and diastolic function both at rest and during exercise in subjects who have received radiotherapy with significant incidental heart dose for the treatment of cancer.
PMID: 32154028 [PubMed]
13:50
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:50
In reply to this message
pubmed: tutte cardiotoxicity...
Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin.
Related Articles
Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin.
Cardiooncology. 2020;6:1
Authors: Li J, Chang HM, Banchs J, Araujo DM, Hassan SA, Wagar EA, Yeh ETH, Meng QH
Abstract
Background: Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity. Recently, global longitudinal peak systolic strain (GLS) measured with speckle tracking echocardiography (STE) and high-sensitivity troponin T (hs-TnT) have been validated as sensitive indicators of doxorubicin-induced cardiotoxicity. Here, we asked whether changes in hs-TnT and/or GLS can be detected in patients who were treated with continuous infusion of doxorubicin or pre-treated with dexrazoxane followed by bolus doxorubicin.
Methods: Twenty-nine patients with newly diagnosed sarcoma were assigned to receive either 72-h doxorubicin infusion or dexrazoxane pre-treatment before bolus doxorubicin. Eight patients received dexrazoxane pre-treatment; eleven patients received continuous doxorubicin infusion; ten patients crossed over from continuous infusion to dexrazoxane. Bloods were collected for hs-TnT at baseline, 24 h or 72 h after initiation of doxorubicin treatment in each chemotherapy cycle. All blood samples were assayed in batch using hs-TnT kit from Roche diagnostics. 2D Echo and STE were performed before doxorubicin, after cycle 3, and at the end of chemotherapy.
Results: Seven patients in the cross-over group have at least one hs-TnT measurement between 5 ng/L to 10 ng/L during and after chemotherapy. Ten patients have at least one hs-TnT measurement above 10 ng/ml during and after chemotherapy (six in dexrazoxane group, three in continuous infusion group, one in cross-over group). The average hs-TnT level increases with each additional cycle of doxorubicin treatment. Eight patients had a more than 5% reduction in LVEF at the end of chemotherapy (four in dexrazoxane group, three in continuous infusion group, and one in cross-over group). Four out of these eight patients had a change of GLS by more than 15% (three in the dexrazoxane group).
Conclusion: Elevation in hs-TnT levels were observed in more than 59% of patients who had received either continuous doxorubicin infusion or dexrazoxane pre-treatment before bolus doxorubicin. However, changes in LVEF and GLS were less frequently observed. Thus, continuous doxorubicin infusion or dexrazoxane pre-treatment do not completely ameliorate subclinical doxorubicin-induced cardiotoxicity as detected by more sensitive techniques.
PMID: 32154027 [PubMed]
13:50
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:50
In reply to this message
pubmed: tutte cardiotoxicity...
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.
Related Articles
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.
Cardiooncology. 2019;5:18
Authors: Bansal N, Adams MJ, Ganatra S, Colan SD, Aggarwal S, Steiner R, Amdani S, Lipshultz ER, Lipshultz SE
Comments
Post a Comment
اكتب تعليق حول الموضوع